Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention

Journal of Cardiovascular Medicine

Volumn 12, Issue 1, 2011, Pages 29-36

  Schiariti, Michele ^a,b   Saladini, Angela ^a   Cuturello, Domenico ^b   Missiroli, Bindo ^a   Puddu, Paolo Emilio ^b  

^a S ANNA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Eptifibatide double bolus; Ischemic events; Percutaneous coronary intervention; Prediction; Randomized GP IIb IIIa; Tirofiban high dose

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; EPTIFIBATIDE; HEPARIN; TENECTEPLASE; TICLOPIDINE; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; AORTA BALLOON; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; INCIDENCE; LOADING DRUG DOSE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; SMOKING HABIT; STENT THROMBOSIS;

AGED; ANGIOPLASTY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; TYROSINE;

EID: 79953718481     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32833cdd04     Document Type: Article

References (28)

1. Topol EJ, Byzova TV, Plow EF. Platelet IIb-IIIa blockers. Lancet 1999; 353:227-231.
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al., American College of Cardiology and American Heart Association Committee on the Management of Patients With Unstable Angina. The ACC/AHA 2002 guideline update of management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40:1366-1374.
3. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:e1-e121.
4. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al., ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrilin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial. a randomized controlled trial. JAMA 2001; 285:2468-2473.
5. Giugliano RP, White JA, Bode CH, Armstrong PW, Montalescot G, Lewis BS, et al., for the EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360:1-15.
6. Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interventions 2009; 73:214-221.
7. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al., TARGET Investigators (Do Tirofiban and ReoPro Give Similar Efficacy Trial). Comparison of two glycoproteins IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894. (Pubitemid 32553357)
8. Bolognese L, Calzini G, Liistro F, Angioli P, Ducci K, Taddei T, et al. Randomized comparison of upstream tirofiban versus downstream high dose tirofiban or abciximab on tissue level perfusion and troponin release in high risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006; 47:522-528. (Pubitemid 43170839)
9. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, et al., for the MULTISTRATEGY Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTI-STRATEGY randomized trial. JAMA 2008; 299:1788-1799.
10. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35:922-928. (Pubitemid 30189923)
11. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 2009; 53:1668-1673.
12. Le Pen C, Lilliu H. Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in? Pharm World Sci 2005; 27:83-91.
13. Brener SJ. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect? J Am Coll Cardiol 2009; 53:1674-1676.
14. Zijlstra F. The benefits and risks of Abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ? Catheter Cardiovasc Interventions 2009; 73:222-223.
15. Schiariti M, Saladini A, Missiroli B, Papalia F, Cuturello D, Puddu PE, Gaudio C. Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna Tirofiban Safety study. J Cardiovasc Med 2010; 11:250-259.
16. Gilchrist IC, O'Shea JC, Kosoglu T, Jennings LK, Lorenz TJ, Kitt MM, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double bolus eptifibatide in percutaneous coronary intervention. Circulation 2001; 104:406-411. (Pubitemid 32678269)
17. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, et al., Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to minimize platelet aggregation and coronary thrombosis-II. J Am Coll Cardiol 1999; 33:88-96.
18. Lindsey JB, Marso SP, Pencina M, Stolker JM, Kennedy KF, Rihal C, et al., on behalf of the EVENT Registry Investigators. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol Intv 2009; 2:1074-1082.
19. Puddu PE, Brancaccio G, Leacche M, Monti F, Lanti M, Menotti A, et al., on behalf of the OP-RISK Study Group. Prediction of early and delayed postoperative deaths after coronary artery bypass surgery in Italy. Multivariate prediction based on Cox and logistic models and a chart based on the accelerated failure time model. Ital Heart J 2002; 3:166-181.
20. Miller Ch C III, Reardon MJ, Safi HJ. Risk stratification. A practical guide for clinicians. Cambridge: Cambridge University Press; 2001. pp. 1-174.
21. Menotti A, Puddu PE, Lanti M. Il rischio in Cardiologia: dalla teoria alla pratica. Pavia: Edizioni Internazionali srl; 2004. pp. 1-189.
22. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100:1199-1206.
23. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
24. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al., PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116:2923-2932.
25. Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, et al., HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009; 54:1438-1446.
26. Blankenship JC, Tasissa G, O'Shea JC, Iliadis EA, Bachour FA, Cohen DJ, et al., ESPRIT Investigators. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001; 38:653-658. (Pubitemid 32835731)
27. Gibson CM, Murphy SA, Marble SJ, Cohen DJ, Cohen EA, Lui HK, et al. Relationship of creatine kinase-myocardial band release to thrombolysis in myocardial infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. Am Heart J 2002; 143:106-110. (Pubitemid 34056382)
28. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al., for the TRANFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360:2705-2718.